Tirzepatide emerges a groundbreaking therapeutic agent for individuals facing type 2 diabetes. As a dual stimulator, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide https://lexiebgif841283.izrablog.com/40899563/tirzepatide-a-novel-glp-1-and-gip-receptor-agonist